TABLE 23CDAI and IBDQ results for all patients in ACCENT I2,3

WeekCDAI: mediana% patients with IBDQ score > 170a
Placebo (n = 188)5 mg/kg (n = 193)10 mg/kg (n = 192)pPlacebo (n = 188)5 mg/kg (n = 193)10 mg/kg (n = 192)p
0292303297NSb,c4.85.28.3NSb,c
2197.5205195NSb,c35.632.335.8NSb,c
6205180180NSb,c33.541.738.3NSb,c
10187.5170167.5< 0.05b,c35.141.739.9NSb,c
14225185182.5< 0.05b,c29.838.040.9NSb< 0.05c
22212.5185167.5< 0.05b,c29.337.044.0NSb < 0.05c
30212.5180177.5NSb < 0.05c33.539.644.0NSb < 0.05c
38200187.5170NSb < 0.05c35.134.947.7NSb < 0.05c
46205190175NSb < 0.05c33.535.448.7NSb < 0.05c
54205185170NSb < 0.05c35.137.546.1NSb < 0.05c

NS, not significant.

a

Data read from graph in Rutgeerts et al.2

b

Comparison: 5 mg/kg group vs placebo.

c

Comparison: 10 mg/kg group vs placebo.

There was no adjustment for repeated measures in the comparisons.

From: 3, Assessment of clinical effectiveness

Cover of A Systematic Review and Economic Evaluation of the Use of Tumour Necrosis Factor-Alpha (TNF-α) Inhibitors, Adalimumab and Infliximab, for Crohn's Disease
A Systematic Review and Economic Evaluation of the Use of Tumour Necrosis Factor-Alpha (TNF-α) Inhibitors, Adalimumab and Infliximab, for Crohn's Disease.
Health Technology Assessment, No. 15.6.
Dretzke J, Edlin R, Round J, et al.
Southampton (UK): NIHR Journals Library; 2011 Feb.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.